IMVT Immunovant Inc.
Health Care, filed as IMMUNOVANT INC (COM), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab
Bought by 1 manager in 2026 Q3, sold by 2
In 2026 Q3 Farallon Capital Management added to Immunovant, while Nathan Fischel and David Einhorn trimmed.
Who owns this now
Largest portfolio weights among holders, up to 1.0% (Nathan Fischel, DAFNA Capital Management). Not free-float ownership.
Who owns IMVT
Sorted by value, long equity only, as of 2026 Q3.
| History | |||||
|---|---|---|---|---|---|
| Farallon Capital Management | Add +11.5% | 6,471,000 | $219M | History | |
| Nathan Fischel, DAFNA Capital Management | Reduce −9.4% | 135,524 | $4.6M | History | |
| David Einhorn, DME Capital Management | Reduce −25.0% | 70,140 | $2.4M | History |
Insider trades
Open-market buys and sales by IMVT's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $350M bought by 1 insider
- $10.7M sold by 5 insiders outside a trading plan
- $601K sold by 2 insiders under 10b5-1 plans
-
Atul Pande DirectorPlanned sale$108K 3,000 shares at $36.00 2.5% of stakeTraded Nov 11 Filed Nov 12
-
Atul Pande DirectorPlanned sale$65K 1,500 shares at $43.27 1.3% of stakeTraded Aug 28 Filed Aug 28
-
Atul Pande DirectorPlanned sale$60K 1,500 shares at $39.80 1.3% of stakeTraded Jul 24 Filed Jul 24
-
Melanie Gloria COOSale$679K 17,714 shares at $38.31 7.3% of stakeTraded Jun 26 Filed Jun 26
-
Jay S. Stout Chief Technology OfficerSale$1.5M 40,000 shares at $38.31 16% of stakeTraded Jun 26 Filed Jun 26
-
Christopher Van Tuyl Chief Legal OfficerSale$683K 17,824 shares at $38.31 9% of stakeTraded Jun 26 Filed Jun 26
-
Tiago Girao CFOSale$385K 10,000 shares at $38.46 3.9% of stakeTraded Jun 26 Filed Jun 26
-
Atul Pande DirectorPlanned sale$57K 1,500 shares at $38.01 1.3% of stakeTraded Jun 26 Filed Jun 26
-
Atul Pande DirectorPlanned sale$51K 1,500 shares at $34.02 1.3% of stakeTraded Jun 15 Filed Jun 16
-
Andrew J. Fromkin DirectorSale$7.4M 221,951 shares at $33.51 75% of stakeTraded May 28 Filed May 29
-
Atul Pande DirectorPlanned sale$192K 6,000 shares at $32.00 4.9% of stakeTraded May 20 Filed May 20
-
Robert Graham Susman DirectorPlanned sale$68K 2,502 shares at $27.17 6.4% of stakeTraded May 1 Filed May 1
-
Roivant Sciences Ltd. DirectorBuy$350M 16.7M shares at $21.00 +17% to stakeTraded Dec 12, 2025 Filed Dec 12, 2025
Also filed in the last 12 months, not counted as buying or selling: 45 sales to cover taxes, 15 option exercises, 11 stock grants, and 3 sales back to the company.
SEC filings
Recent issuer filings from EDGAR, 10 shown.
Financials
US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.
Income statement
Balance sheet
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total current assets | $404.33M | $665.77M | $767.66M | $948.82M |
| Total non-current assets * | $1.5M | $0.595M | $8.56M | $8.2M |
| Total assets | $405.84M | $666.36M | $776.22M | $957.01M |
| Total current liabilities | $43.3M | $48.61M | $68.78M | $104.42M |
| Total non-current liabilities * | $47,000 | $0.00 | $0.00 | $0.00 |
| Total equity | $362.49M | $617.76M | $707.45M | $852.59M |
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon